What Happened

Vertex Pharmaceuticals presented new Phase 3 data on ALYFTREK at the European Cystic Fibrosis Conference. The data showed that 65% of children aged 2-5 achieved sweat chloride levels below 30 mmol/L, a key marker of CFTR function restoration.

Who Is Affected

Children aged 2-5 with cystic fibrosis and specific genotypes (F/F and F/MF) are the primary focus of this study. Older patients aged 6 and above also benefit from ALYFTREK's long-term safety and efficacy profile.

Market Impact

• Vertex plans to initiate global regulatory submissions for ALYFTREK in the first half of 2026.
• The data positions ALYFTREK as a leading treatment for younger CF patients, expanding Vertex's market reach.

What to Watch

Monitor Vertex's progress with global regulatory submissions for ALYFTREK and TRIKAFTA, especially for younger patient groups. The upcoming regulatory decisions will significantly impact the CF treatment landscape.